Assignee
LUNELLA BIOTECH INC
CA·28 granted patents·15 pending applications·14 citations·filing 2018–2025
Top patents by PatentIndex Score
43 records- 0193US12208111B2Azithromycin and roxithromycin derivtives as senolytic drugsLUNELLA BIOTECH INC·Filed 2024·Granted Jan 28, 2025·1 cites·8 claims
- 0291US10512618B2Mitoriboscins: mitochondrial-based therapeutics targeting cancer cells, bacteria, and pathogenic yeastLUNELLA BIOTECH INC·Filed 2018·Granted Dec 24, 2019·4 cites·8 claims
- 0387US10980821B2Triphenylphosphonium-derivative compounds for eradicating cancer stem cellsLUNELLA BIOTECH INC·Filed 2018·Granted Apr 20, 2021·2 cites·27 claims
- 0485US11364210B2Mitoriboscins: mitochondrial-based therapeutics targeting cancer cells, bacteria and pathogenic yeastLUNELLA BIOTECH INC·Filed 2019·Granted Jun 21, 2022·1 cites·9 claims
- 0584US11957700B2Azithromycin and roxithromycin derivatives as senolytic drugsLUNELLA BIOTECH INC·Filed 2019·Granted Apr 16, 2024·1 cites·14 claims
- 0683US11547679B2Mitoriboscins: mitochondrial-based therapeutics targeting cancer cells, bacteria and pathogenic yeastLUNELLA BIOTECH INC·Filed 2019·Granted Jan 10, 2023·1 cites·3 claims
- 0782US11672810B2Therapeutics and methods for predicting and overcoming endocrine resistance in breast cancerLUNELLA BIOTECH INC·Filed 2020·Granted Jun 13, 2023·1 cites·30 claims
- 0881US11311501B2Mitoriboscins: mitochondrial-based therapeutics targeting cancer cells, bacteria, and pathogenic yeastLUNELLA BIOTECH INC·Filed 2018·Granted Apr 26, 2022·1 cites·9 claims
- 0981US2025120994A1Azithromycin and roxithromycin derivatives as senolytic drugsLUNELLA BIOTECH INC·Filed 2024·Application pending·0 cites
- 1078US12006553B2Companion diagnostics for mitochondrial inhibitorsLUNELLA BIOTECH INC·Filed 2018·Granted Jun 11, 2024·1 cites·9 claims
- 1177US2024316086A1Triple combination therapies for anti-agingLUNELLA BIOTECH INC·Filed 2024·Application pending·0 cites
- 1274US11229657B2Targeting hypoxic cancer stem cells (CSCs) with doxycycline: implications for improving anti-angiogenic therapyLUNELLA BIOTECH INC·Filed 2018·Granted Jan 25, 2022·1 cites·16 claims
- 1374US2024116942A1Selective cdk 4/6 inhibitor cancer therapeuticsLUNELLA BIOTECH INC·Filed 2023·Application pending·0 cites
- 1471US11918597B2Triple combination therapies for anti-agingLUNELLA BIOTECH INC·Filed 2019·Granted Mar 5, 2024·0 cites·16 claims
- 1571US11865124B2Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (CSCS)LUNELLA BIOTECH INC·Filed 2021·Granted Jan 9, 2024·0 cites·8 claims
- 1671US11865130B2Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cellsLUNELLA BIOTECH INC·Filed 2021·Granted Jan 9, 2024·0 cites·17 claims
- 1770US12553092B2Energetic cancer stem cells (E-CSCS): a new hyper-metabolic and proliferative tumor cell phenotype, driven by mitochondrial energyLUNELLA BIOTECH INC·Filed 2022·Granted Feb 17, 2026·0 cites·8 claims
- 1870US11964983B2Selective CDK4/6 inhibitor cancer therapeuticsLUNELLA BIOTECH INC·Filed 2021·Granted Apr 23, 2024·0 cites·5 claims
- 1970US2022339125A1Mitoriboscins: mitochondrial-based therapeutics targeting cancer cells, bacteria, and pathogenic yeastLUNELLA BIOTECH INC·Filed 2022·Application pending·0 cites
- 2069US11738034B2Triphenylphosphonium-derivative compounds for eradicating cancer stem cellsLUNELLA BIOTECH INC·Filed 2021·Granted Aug 29, 2023·0 cites·18 claims
- 2167US11197872B2Vitamin C and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (CSCs)LUNELLA BIOTECH INC·Filed 2018·Granted Dec 14, 2021·0 cites·6 claims
- 2266US2022096502A1Targeting hypoxic cancer stem cells (cscs) with doxycycline: implications for improving anti-angiogenic therapyLUNELLA BIOTECH INC·Filed 2021·Application pending·0 cites
- 2365US11160821B2Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cellsLUNELLA BIOTECH INC·Filed 2018·Granted Nov 2, 2021·0 cites·6 claims
- 2464US11441195B2Energetic cancer stem cells (e-CSCs): a new hyper-metabolic and proliferative tumor cell phenotype, driven by mitochondrial energyLUNELLA BIOTECH INC·Filed 2019·Granted Sep 13, 2022·0 cites·25 claims
- 2563US11497749B2Mitoflavoscins: targeting flavin-containing enzymes eliminates cancer stem cells (CSCS) by inhibiting mitochondrial respirationLUNELLA BIOTECH INC·Filed 2018·Granted Nov 15, 2022·0 cites·19 claims
- 2663US2025304591A1SUBSTITUTED PYRROLO[2,3-d]PYRIMIDINES AS SELECTIVE CDK 4/6 INHIBITORSLUNELLA BIOTECH INC·Filed 2025·Application pending·0 cites
- 2763US2025206713A12-[(2-oxo-4-phenyl-2h-chromen-7-yl)oxy] propanamido derivativesLUNELLA BIOTECH INC·Filed 2023·Application pending·0 cites
- 2862US11667639B2Mitoketoscins: mitochondrial-based therapeutics targeting ketone metabolism in cancer cellsLUNELLA BIOTECH INC·Filed 2018·Granted Jun 6, 2023·0 cites·7 claims
- 2962US11561227B2Anti-mitochondrial inhibitors for oncogenic Ras and MycLUNELLA BIOTECH INC·Filed 2018·Granted Jan 24, 2023·0 cites·10 claims
- 3061US12358920B2Substituted pyrrolo[2,3-d]pyrimidines as selective CDK 4/6 inhibitorsLUNELLA BIOTECH INC·Filed 2020·Granted Jul 15, 2025·0 cites·19 claims
- 3161US11667640B2Mitoketoscins: mitochondrial-based therapeutics targeting ketone metabolism in cancer cellsLUNELLA BIOTECH INC·Filed 2020·Granted Jun 6, 2023·0 cites·6 claims
- 3257US2025049823A1Mitochondrial atp inhibitors targeting the gamma subunit prevent metastasisLUNELLA BIOTECH INC·Filed 2022·Application pending·0 cites
- 3355US2023172879A1Therapeutic methods for preventing tumor metastasis and tumor recurrenceLUNELLA BIOTECH INC·Filed 2021·Application pending·0 cites
- 3454US11559527B2Targeting mitochondrial fission through mDIVI-1 derivativesLUNELLA BIOTECH INC·Filed 2018·Granted Jan 24, 2023·0 cites·8 claims
- 3553US12188936B2Biomarkers and therapeutics for endocrine therapy resistanceLUNELLA BIOTECH INC·Filed 2019·Granted Jan 7, 2025·0 cites·35 claims
- 3652US11497759B2Repurposcins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cellsLUNELLA BIOTECH INC·Filed 2018·Granted Nov 15, 2022·0 cites·17 claims
- 3752US2024010622A1Mitochondrial atp inhibitors targeting the gamma subunit prevent metastasisLUNELLA BIOTECH INC·Filed 2021·Application pending·0 cites
- 3850US2022249438A1Carbocyanine compounds for targeting mitochondria and eradicating cancer stem cellsLUNELLA BIOTECH INC·Filed 2020·Application pending·0 cites
- 3950US2023174464A1Myristoyl derivatives of 9-amino-doxycycline for targeting cancer stem cells and preventing metastasisLUNELLA BIOTECH INC·Filed 2021·Application pending·0 cites
- 4049US12319690B2Selective CDK 4/6 inhibitor cancer therapeuticsLUNELLA BIOTECH INC·Filed 2020·Granted Jun 3, 2025·0 cites·15 claims
- 4149US2022211728A1Alkyl-tpp compounds for mitochondria targeting and anti-cancer treatmentsLUNELLA BIOTECH INC·Filed 2020·Application pending·0 cites
- 4249US2022040316A1Triple combination therapies for targeting mitochondria and killing cancer stem cellsLUNELLA BIOTECH INC·Filed 2019·Application pending·0 cites
- 4347US2022365069A1Atp-based cell sorting and hyperproliferative cancer stem cellsLUNELLA BIOTECH INC·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when LUNELLA BIOTECH INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →